TEG-based transfusion protocol is associated with decreased blood product use without increased risk of hemoperitoneum.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
27
03
2023
accepted:
14
08
2023
medline:
30
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
Thromboelastography (TEG) informs the need for blood product transfusions to prevent procedural bleeding complications in patients with cirrhosis. We aimed to evaluate the impact of using a TEG-based transfusion protocol on blood product utilization before paracentesis and the post-paracentesis hemoperitoneum (PPH) incidence. We conducted an ambispective analysis of patients with cirrhosis who underwent paracentesis from 2017 to 2021. In May 2019, we enacted a TEG-based transfusion protocol to guide pre-paracentesis blood product use. Patients with platelets < 20,000 or international normalized ratio ≥ 4 underwent TEG and received blood products if r value > 10 min or MA <30 mm. Patients were divided into pre-TEG and post-TEG protocol cohorts based on the date of paracentesis. Pre-paracentesis blood product transfusions in the form of platelets, fresh frozen plasma, and cryoprecipitates were recorded. PPH was defined as a decrease in hemoglobin of ≥1 g and the presence of blood on diagnostic imaging and/or the need for therapeutic intervention. A total of 483 patients underwent 1281 paracenteses. The main etiologies of cirrhosis were alcohol (43%) and NASH (25%), and the mean MELD-sodium was 22±6. Pre-TEG and post-TEG protocol cohort sizes were similar: 253 patients and 607 paracenteses versus 230 patients and 674 paracenteses. After TEG-protocol implementation, blood product transfusions decreased significantly (228 vs. 49 products, p<0.001) with associated cost savings. One patient in each cohort developed PPH. Implementation of a pre-paracentesis TEG-based transfusion protocol for patients with cirrhosis successfully resulted in decreased blood product use with no associated increase in incidence of PPH.
Sections du résumé
BACKGROUND
Thromboelastography (TEG) informs the need for blood product transfusions to prevent procedural bleeding complications in patients with cirrhosis. We aimed to evaluate the impact of using a TEG-based transfusion protocol on blood product utilization before paracentesis and the post-paracentesis hemoperitoneum (PPH) incidence.
METHODS
We conducted an ambispective analysis of patients with cirrhosis who underwent paracentesis from 2017 to 2021. In May 2019, we enacted a TEG-based transfusion protocol to guide pre-paracentesis blood product use. Patients with platelets < 20,000 or international normalized ratio ≥ 4 underwent TEG and received blood products if r value > 10 min or MA <30 mm. Patients were divided into pre-TEG and post-TEG protocol cohorts based on the date of paracentesis. Pre-paracentesis blood product transfusions in the form of platelets, fresh frozen plasma, and cryoprecipitates were recorded. PPH was defined as a decrease in hemoglobin of ≥1 g and the presence of blood on diagnostic imaging and/or the need for therapeutic intervention.
RESULTS
A total of 483 patients underwent 1281 paracenteses. The main etiologies of cirrhosis were alcohol (43%) and NASH (25%), and the mean MELD-sodium was 22±6. Pre-TEG and post-TEG protocol cohort sizes were similar: 253 patients and 607 paracenteses versus 230 patients and 674 paracenteses. After TEG-protocol implementation, blood product transfusions decreased significantly (228 vs. 49 products, p<0.001) with associated cost savings. One patient in each cohort developed PPH.
CONCLUSION
Implementation of a pre-paracentesis TEG-based transfusion protocol for patients with cirrhosis successfully resulted in decreased blood product use with no associated increase in incidence of PPH.
Identifiants
pubmed: 37889553
doi: 10.1097/HC9.0000000000000292
pii: 02009842-202311010-00013
pmc: PMC10615392
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
Clin Liver Dis (Hoboken). 2016 Feb 26;7(2):26-28
pubmed: 31041022
Hepatology. 2020 Jan;71(1):235-246
pubmed: 31148204
J Hepatol. 2010 Aug;53(2):362-71
pubmed: 20546962
Hepatology. 2005 Mar;41(3):553-8
pubmed: 15726661
Dig Dis Sci. 2022 Nov;67(11):5290-5299
pubmed: 35122595
Blood Coagul Fibrinolysis. 2001 Jul;12(5):327-37
pubmed: 11505075
Health Technol Assess. 2015 Jul;19(58):1-228, v-vi
pubmed: 26215747
Transfus Med Rev. 2012 Jan;26(1):1-13
pubmed: 21872428
Blood Transfus. 2021 May;19(3):197-204
pubmed: 33000753
Transfus Apher Sci. 2009 Apr;40(2):119-23
pubmed: 19249246
Gastroenterology. 2021 Nov;161(5):1615-1627.e1
pubmed: 34579936
Hepatology. 2006 Aug;44(2):440-5
pubmed: 16871542
Semin Liver Dis. 2022 Aug;42(3):341-361
pubmed: 35764316
Hepatology. 2008 Dec;48(6):2064-77
pubmed: 19003880
Hepatology. 1986 Jan-Feb;6(1):79-86
pubmed: 3943792
Dig Liver Dis. 2016 May;48(5):455-467
pubmed: 27012444
Hepatology. 2004 Aug;40(2):484-8
pubmed: 15368454
J Vasc Interv Radiol. 2019 Aug;30(8):1168-1184.e1
pubmed: 31229333
J Clin Gastroenterol. 2020 Mar;54(3):255-262
pubmed: 31008867
Am J Med Sci. 1990 Dec;300(6):372-9
pubmed: 2264575
Hepatology. 2016 Feb;63(2):566-73
pubmed: 26340411
J Hepatol. 2010 Mar;52(3):355-61
pubmed: 20132999
BMC Nephrol. 2013 Oct 10;14:217
pubmed: 24107093